NICE has approved the combination of Braftovi (encorafenib) and Erbitux (cetuximab) for BRAF V600E-mutated metastatic colorectal cancer following an improved pricing agreement.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.